Xbiotech Stock Total Asset
| XBIT Stock | USD 7.61 0.26 3.54% |
XBiotech fundamentals help investors to digest information that contributes to XBiotech's financial success or failures. It also enables traders to predict the movement of XBiotech Stock. The fundamental analysis module provides a way to measure XBiotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XBiotech stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 226.6 M | 209.4 M | |
| Intangibles To Total Assets | (0.08) | (0.09) |
XBiotech | Total Asset |
XBiotech Company Total Asset Analysis
XBiotech's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current XBiotech Total Asset | 226.62 M |
Most of XBiotech's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XBiotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
XBiotech Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for XBiotech is extremely important. It helps to project a fair market value of XBiotech Stock properly, considering its historical fundamentals such as Total Asset. Since XBiotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XBiotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XBiotech's interrelated accounts and indicators.
Click cells to compare fundamentals
XBiotech Total Asset Historical Pattern
Today, most investors in XBiotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XBiotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of XBiotech total asset as a starting point in their analysis.
XBiotech Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
XBiotech Total Assets
Total Assets |
|
Based on the latest financial disclosure, XBiotech has a Total Asset of 226.62 M. This is 96.99% lower than that of the Biotechnology sector and 88.53% lower than that of the Health Care industry. The total asset for all United States stocks is 99.23% higher than that of the company.
XBiotech Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XBiotech's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XBiotech could also be used in its relative valuation, which is a method of valuing XBiotech by comparing valuation metrics of similar companies.XBiotech is currently under evaluation in total asset category among its peers.
XBiotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of XBiotech from analyzing XBiotech's financial statements. These drivers represent accounts that assess XBiotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XBiotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 726.9M | 482.4M | 334.4M | 106.8M | 122.9M | 116.7M | |
| Enterprise Value | 12.3M | 245.0M | 97.4M | (50.5M) | (58.0M) | (55.1M) |
XBiotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, XBiotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to XBiotech's managers, analysts, and investors.Environmental | Governance | Social |
XBiotech Institutional Holders
Institutional Holdings refers to the ownership stake in XBiotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of XBiotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XBiotech's value.| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 77.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | Empowered Funds, Llc | 2024-06-30 | 69.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | Fmr Inc | 2024-09-30 | 29 K | Nuveen Asset Management, Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 23.6 K | Rhumbline Advisers | 2024-06-30 | 20.1 K | Citigroup Inc | 2024-09-30 | 14.5 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 1.1 M |
XBiotech Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | 58.86 M | ||||
| Shares Outstanding | 30.48 M | ||||
| Shares Owned By Insiders | 35.10 % | ||||
| Shares Owned By Institutions | 16.18 % | ||||
| Number Of Shares Shorted | 848.26 K | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 12.23 X | ||||
| Revenue | 300 K | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (35.77 M) | ||||
| Net Income | (24.56 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 7.77 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 6.31 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Short Ratio | 16.65 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 231.98 M | ||||
| Total Asset | 226.62 M | ||||
| Retained Earnings | (52.31 M) | ||||
| Working Capital | 195.62 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
| Net Asset | 226.62 M |
About XBiotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XBiotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XBiotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XBiotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.